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 Atherosclerosis is a protean disease 
aff ecting disparate arterial territories 
and showing disparate links with Framin-
gham (classical) risk factors. Cholesterol 
dominates the scene in ischemic heart 
disease, hypertension in cerebrovascular 
disease, and diabetes and smoking in 
peripheral artery disease. Beyond classi-
cal and genetically determined risk fac-
tors, substantial evidence has now 
accrued that chronic conditions such as 
immune-mediated and infl ammatory 
diseases and chronic kidney disease 
(CKD) oft en underlie very severe arte-
rial disease. Given the 10 % frequency of 
CKD at the population level, under-
standing why atherosclerosis engenders 
a high risk in these patients is of obvious 
importance both for public health and 
for clinical reasons. 
 Knowledge about the composition, 
structure, and distribution of atheroscle-
rotic lesions is a fundamental starting 
point for understanding the high risk for 
clinical events in atherosclerosis. This 
knowledge was effi  caciously summarized 
in a scientifi c statement by the American 
Heart Association, which gave a numeri-
cal classifi cation of histological lesions 
(updated by Stary 1 in 2000) ( Figure 1 ). 
Initial lesions in the intimal layer (types 
I – III, from infi ltration of macrophages 
and their transformation into foam cells 
to confl uence into a lipid core) are small 
and silent, while types IV – VI lesions may 
produce clinical events or may remain 
silent, leaving the lumen unobstructed. 
The most critical lesion is the type VI 
lesion, where surface defects, hematoma, 
and thrombosis concur in making the 
plaque quite unstable and risky both 
locally and systemically. Th e three com-
ponents of type VI lesions are variously 
interrelated. Th us a fi ssure may engender 
hematoma with or without thrombus or 
remain an isolated lesion, and a stenosing 
thrombus may grow on an intimal surface 
without evident  fi ssure. Clinical events 
may occur in the presence of type IV 
(accumulation of a substantial lipid core 
with an overlying intimal thickening) or 
type V lesions (prominent lipid core cou-
pled with a fi bromuscular cap) when these 
lesions become obstructive. Types IV – V 
lesions evolve frequently into calcifi ed 
plaques (type VII) and, less commonly, 
into predominantly fi brous lesions (type 
VIII). In type V lesions the fi bromuscular 
cap replaces intima disrupted by the lipid 
core or thrombi. A fundamental diff er-
ence between types IV and V lesions is 
that, in the latter, smooth muscle cells are 
not properly aligned and do not show the 
adaptive thickening of normal intima. 
Types I – III lesions may in part regress, but 
from stage IV on, progression is the rule. 
Type VI lesions may enter into a risky 
vicious cycle whereby repeated fi ssura-
tions and the ensuing hematoma and 
thrombus formation may rapidly generate 
severe stenosis ( Figure 1 ). 
 Th ere is still a paucity of anatomical stud-
ies on arterial disease in patients with CKD. 
In a very recent series of 46 CKD patients 
with advanced carotid stenosis (  >  70 % ) 
submitted to surgery, 2 carotid plaques were 
more frequently calcifi ed (17 % vs 7 % ) than 
plaques in a parallel series of 56 patients 
with normal renal function and similarly 
occlusive carotid lesions. In addition, in 
CKD patients, plaques were more fre-
quently unstable (83 vs 52 % ) and ruptured 
(59 vs 36 % ) than in controls. Importantly, 
the fibrous component was markedly 
reduced in CKD patients (40 vs 57 % ), sug-
gesting that this alteration may be a relevant 
driver of plaque instability and rupture in 
this condition. 
 Anatomical studies apart, reliable imag-
ing techniques are needed in order to 
investigate in detail the dynamics of arte-
rial lesions in human diseases. Modern 
techniques such as positron emission tomo-
graphy with fl uorodeoxyglucose 3 allow 
quantifi cation of the infl ammatory com-
ponent of the process (macrophage infi l-
tration), while nuclear magnetic resonance 
imaging, 4 intra-arterial ultrasound, 5 and 
optical coherence tomography 6 allow 
defi nition of the type of lesions that almost 
perfectly matches that of lesions by histo-
logy. Although less accurate and informa-
tive than nuclear magnetic resonance and 
other more recent techniques, standard 
noninvasive ultrasound studies of carotid 
arteries provide precious information for 
the staging of atherosclerosis in large stud-
ies. Coupling these techniques with the 
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measurement of biochemical markers of 
the atherosclerosis process — for example, 
serum lipids or C-reactive protein — is a 
standard approach to investigate the origin 
and the evolution of arterial lesions in 
human diseases. 
 Detailed biochemical studies of athero-
sclerosis in animal models and in samples 
taken during surgery have coherently 
shown that the actual amount of fi brous 
tissue in the plaque depends on the bal-
ance between collagenous matrix synthe-
sis by smooth muscle cells and degradation 
by proteases. Matrix synthesis may be 
reduced because of decreased smooth 
muscle cell content as a result of apoptosis 
of these cells triggered by infl ammation 7 
or because matrix is broken down by high 
levels of proteases secreted by infi ltrating 
macrophages. Inflammation alters the 
balance between proteases and their 
inhibitors (tissue inhibitors of metallopro-
teinases (TIMPs)). Th e matrix metallo-
proteinases (MMPs) MMP-1, MMP-3, 
MMP-8, and MMP-9 are abundant in 
unstable, risky type V lesions, particularly 
in the cap region, which is a critical site for 
plaque stability. More recent studies have 
shown that infl ammatory stimuli induce 
MMP-10, a stromelysin, in endothelial 
cells  in vitro and that this protease is actu-
ally expressed in atherosclerotic lesions in 
humans. 8 Furthermore, neo-angiogenesis 
contributes substantially to the potential 
of the plaque to generate clinical events, 
both because hemorrhage resulting from 
neovessel rupture may result in plaque 
rupture and because a rich neovessel net-
work may enhance the recruitment 
of inflammatory cells and the ensuing 
burden of matrix-degrading proteases in 
the plaque. 
 A role of increased MMPs in the patho-
genesis of clinical events in patients with 
atherosclerosis is well established. 9 On 
the other hand, as is summarized above, 
recent pathology studies in CKD patients 
with severe carotid stenosis show that 
plaques in these patients present a 
reduced fi brous component as compared 
with similarly occlusive plaques in con-
trols without CKD. 2 Th ese anatomical 
observations are in line with longitudinal 
studies documenting that infl ammation 
(a potent inducer of proteases 7 ) predicts 
clinical events in end-stage renal disease 
patients, 10 as well as with fi ndings docu-
menting that MMP-9 levels correlate with 
carotid atherosclerosis independently of 
other factors in stages 2 – 5 CKD. 11 Coll 
 et al. 12 (this issue) now describe the 
results of a fairly large survey including 
111 patients with CKD of various seve-
rity, 217 end-stage renal disease patients, 
and 50 healthy controls. Here the severity 
of atherosclerosis is estimated on the basis 
of a composite score, which combines the 
results of ankle – brachial index, a hemo-
dynamic surrogate of arterial stenosis in 
the legs, and intima – media thickness as 
detected by standard carotid ultrasound 
studies. Remarkably, in this study the 
severity of atherosclerosis went nicely 
along with MMP-8 and MMP-10 levels 
across the entire spectrum of CKD sever-
ity from stage 2 to stage 5D, and on mul-
tiple regression analysis, MMP-10, 
end-stage renal disease, C-reactive pro-
tein, age, and male gender emerged as the 
sole independent correlates of the sever-
ity of atherosclerosis. Th ese data generate 
the hypothesis that the reduced fi brous 
content found in anatomical studies 
in CKD patients, an alteration that may 
trigger the vicious cycle schematized in 
 Figure 1 , is at least in part the conse-
quence of enhanced MMP-10 activity. 
The purely cross-sectional nature of 
observations in the study by Coll  et al. 12 
and the choice of a composite score rather 
than precise arterial lesions as study end 
points represent obvious methodological 
weaknesses. Cross-sectional studies and 
case-control studies have a low rank in 
the ladder of evidence. Yet insightful 
stimuli for generating new hypotheses 
oft en originate in just these studies. Given 
the sparse number of observations on 
protease activity in atherosclerosis in 
CKD, these authors are to be compli-
mented for their novel, stimulating fi nd-
ings that bring fresh air into a research 
area that has been until now too focused 
on calcification mechanisms. Future 
 Figure 1  |  Histological classification of atherosclerotic lesions. This updated classification of the 
American Heart Association 1 is discussed in detail in the main text. Thick lines identify preferential 
pathways of lesion evolution. The red box highlights type VI plaques, which are the riskiest lesions. 
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studies should now look at the associa-
tion of MMP-10 (and other proteases and 
their inhibitors) with the infl ammatory 
component of atherosclerosis as meas-
ured by fluorodeoxyglucose positron 
emission tomography imaging, and with 
stable and unstable atherosclerotic lesions 
as identifi ed by nuclear magnetic reso-
nance or other advanced imaging meth-
ods. Cutting-edge methods now allow 
MMP activity to be measured  in vivo , 
and these are being explored in experi-
mental research, 13 which off ers tremen-
dous opportunities for investigators 
interested in this fascinating and promis-
ing research issue. Finally, the predictive 
power of MMPs for clinical events needs 
to be addressed in well-powered cohort 
studies and, ultimately, in clinical trials. 
MMP activity can be reduced by sele-
ctive or unselective MMP inhibitors, by 
control of the infl ammatory component 
of atherosclerosis, or by a combination of 
these interventions. Even though no clear 
(experimental) treatment strategy target-
ing MMPs has emerged until now, dys-
regulated metalloproteinase activity 
remains a valid research goal for therapy 
of unstable, risky atherosclerotic lesions, 9 
and clinicians should stay tuned in to 
this translational territory of cardiovas-
cular medicine. 
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 Acute kidney injury (AKI) is still a major 
clinical problem. It is diagnosed in 1 % of 
hospital admissions, and up to 7 % of 
hospitalized patients develop AKI. 
Twenty-fi ve percent of patients in inten-
sive care units develop AKI, and 20 % of 
them will need renal replacement 
therapy. Dialysis is the only treatment 
approved by the US Food and Drug 
Administration for AKI, and the mortal-
ity of AKI is as high as 80 % in intensive 
care unit patients. AKI remains an inde-
pendent risk factor for mortality and 
morbidity, especially in patients under-
going thoracoabdominal aortic surgery, 
cardiac surgery, or bone marrow trans-
plantation, in those receiving ampho-
tericin B or cisplatin therapies, and in 
patients with liver cirrhosis. 1 
 Current AKI diagnosing and staging 
criteria are entirely based on an increase 
in serum creatinine or a decrease in 
urine output. Serum creatinine changes 
are unacceptably insensitive markers of 
AKI, as creatinine levels increase in 
blood only after marked reduction of 
glomerular fi ltration, hence when kidney 
injury has already progressed. 1 In addi-
tion, urine output is aff ected by the use 
of diuretics or by prerenal azotemia. 
Published animal studies clearly demon-
strated that, to be eff ective, treatment of 
AKI should be started very early aft er the 
insult and well before the rise of serum 
creatinine. Thus, sensitive biologic 
 Klotho in acute kidney 
injury: biomarker, therapy, 
or a bit of both ? 
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 Acute kidney injury (AKI) diagnosis is based on an increase in serum 
creatinine or a decrease in urine output. To be effective, treatment of AKI 
should be started very early after the insult and well before the rise of 
serum creatinine. Thus, sensitive biologic markers of renal tubular injury 
in AKI are strongly needed. Hu  et al. suggest that Klotho could be a novel 
biomarker and therapeutic target of ischemia-induced AKI. 
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